The combination of two quantitative Aspergillus PCR assays, targeting a mitochondrial and a ribosomal target (AfQPCR), has proved effective for diagnosing invasive aspergillosis (IA) in hematology patients with risk factors and a positive galactomannan antigen (GM). The aim of the present study was to assess the performance of systematic AfQPCR for IA screening in at risk patients in a hematology intensive care unit (ICU). The study was performed in the hematology ICU at Besanç on University Hospital from March 2012 to December 2013. GM detection (Platelia Aspergillus, Biorad, France) and AfQPCR were performed on the same serum sample, twice a week, in all patients with risk factors for IA. Risk factors and clinical, radiological, and biological data were prospectively recorded using the information sheet from the French network for the surveillance of Invasive Fungal Infection. Thirty-two patients were diagnosed with proven, probable, or possible IA according to the 2008 EORTC/MSG criteria. Sixteen patients had a positive AfQPCR: 9/16 had a positive GM at the same time (GM index >0.5), 4/16 had a positive GM before the AfQPCR and 3/16 had a negative GM at the time of the positive AfQPCR. Screening at risk patients using both AfQPCR and GM on the same serum sample is very feasible in a routine clinical setting. Our results confirm the usefulness of combining biomarkers for an early IA diagnosis.
Introduction
Invasive aspergillosis (IA) remains a clinically challenging opportunistic fungal infection and leads to significant morbidity and mortality in heavily immunocompromised patients. The early diagnosis of IA and the prompt initiation of antifungal therapy have been shown to reduce mortality in patients with IA [1] . Diagnosis of IA is rarely proven by histological examination and is frequently a probable or possible diagnosis based on a combination of clinical, radiological with and without microbiological criteria [2, 3] . Aspergillus galactomannan (GM) antigen is the biomarker most often used in current practice to screen for aspergillosis in leukemia patients [3] .
Although polymerase chain reaction (PCR) assays have the potential to detect quickly a low quantity of fungal DNA in blood samples, they are still not included in the EORTC/MSG for the definitions of IFI due to limited standardisation of PCR procedures [2, 4] . Several studies supporting the hypothesis that QPCR assays provide excellent sensitivity and may accelerate IFI diagnosis have recently been published [3, 5] . A recent biomarker-based diagnostic strategy suggested that the use of galactomannan and PCR could replace culture and histology for the diagnosis of invasive aspergillosis and as a practical trigger for commencement of antifungal treatment in routine clinical practice [6] .
The fact that combining two quantitative Aspergillus PCR assays, targeting a mitochondrial and a ribosomal target (AfQPCR), improves early IA diagnosis in hematology patients with risk factors and a positive GM has been reported previously [7] . However, in the previous study, Aspergillus circulating DNA detection using AfQPCR was done only when GM was positive, and the systematic use of AfQPCR was not assessed.
The aim of the present study was to assess the performance of systematic AfQPCR for IA screening in at risk patients in a Hematology Intensive Care Unit (ICU).
Methods

Patients
The Hematology ICU of the University Hospital of Besançon hospitalizes around 275 patients per year. Each year, around 40 chemotherapy with severe neutropenia (induction and consolidation) and 50 allografts are performed in the Hematology ICU. The study was performed in the Hematology ICU at Besançon University Hospital from March 2012 to December 2013 (21 months); 185 patients out of 480 admissions were included in the study. GM detection and AfQPCR were performed on the same serum sample, twice a week, in all patients with risk factors for IA (severe and prolonged neutropenia, aplasia). Risk factors and clinical, radiological, and biological data were prospectively recorded using the information sheet from the French network for the surveillance of IA. Thirty-two patients were diagnosed with proven, probable or possible IA according to the 2008 EORTC/MSG criteria (2 proven, 28 probable, 2 possible).
Galactomannan (GM) testing
The GM test was performed as part of twice-a-week systematic surveillance of all the patients presenting with host factors of IA monitored in our hematology unit. GM antigenemia was determined using the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay (Bio-Rad, Marnes la Coquette, France), using an index of 0.5 as a positive threshold.
Aspergillus fumigatus QPCR assays
Automatic DNA extraction was performed using 1 ml of serum with a Large Volume MagNa Pure Nucleic Acid Isolation Kit on a MagNa Pure Compact apparatus (Roche Diagnostics, Meylan, France). Elution was performed in a 50 μl volume. DNA extraction from bronchoalveolar lavage fluid (BALF) was performed using 200 μl of BALF pellet with the same kit. Detection of fungal DNA was performed with 10 μl of extract, using two different QPCR assays. The ribosomal QPCR assay, targeting the 18S gene, was performed as described previously using primers AfumiR1/A fumiF1 and a hydrolysis probe A fumiP1 [7, 8] . The mitochondrial QPCR assay was performed using primers and hydrolysis probes described by Costa et al. in 2001 [9] . For each assay, the PCR mix was prepared in a 20 μl final volume using the LightCycler R 480 Probes Master (Roche Diagnostics, Meylan, France): 11 μl of Master mix containing the probe (0.08 μM) and primers (1 μM) and 9 μl DNA. The two Aspergillus PCR were performed as individual assays during the same run, on a LightCycler R 480 Instrument II (Roche Diagnostics). The thermal cycling conditions were as follows: an initial denaturation step at 95
• C for 10 min, followed by 50 cycles of 15 sec at 95
• C and one min at 60
• C. Quantitative results were expressed by determining the detection threshold, or quantification cycle (Cq), that marked the cycle at which fluorescence of the sample became significantly different from the baseline signal. Thus, the higher the Cq, the smaller the amount of DNA in the sample. For both PCR assays, samples were run in duplicates. A sample was considered positive when at least one replicate, for either the ribosomal or the mitochondrial assay, had a Cq < 43 cycles.
Results
From March 2012 to December 2013, 1393 sera were tested corresponding to 185 patients. Thirty-two patients were diagnosed with proven, probable or possible IA according to the 2008 EORTC/MSG criteria (2 proven, 28 probable, 2 possible). Twenty-four patients were classified as non-IA patients but presented either radiological abnormalities or biological positivity (GM, Aspergillus PCR, culture). For the remaining 130 patients of the cohort, the assays were all negative (GM, Aspergillus PCR, culture). AfQPCR was positive for 40 patients: for 18 patients, AfQPCR was positive while GM was negative, and for 22 patients, AfQPCR and GM were positive. Sixteen out of 32 patients classified with IA had a positive AfQPCR (15 probable, 1 possible) ( Table 1 ). For 9/14 cases of probable IA, GM and AfQPCR were positive at the same time, for 4/14, GM was positive before AfQPCR (time lapse 2 to 10 days), for 1/14 AfQPCR was positive one day before the culture (GM remained negative, P15, Table 1 ), the GM remained negative although the index did increase over time; thoracic imagery showed two nodules and AfQPCR was positive. The sensitivity of the AfQPCR assay was 50% when combining both Af targets (46% when using only the ribosomal target and 13% when using only the mitochondrial one). The calculation of the sensitivity for the AfQPCR assay was based on the number of positive AfQPCR/number of proven and probable AI patients (possible AI were excluded).
The 16 other patients classified with IA had no positive AfQPCR on serum samples. However, two of them had positive AfQPCR on broncho-alveolar fluid with Ct ≤ 30 for both targets (Table 2) .
Twenty-four patients were not classified as IA based on EORTC criteria [2] and had positive AfQPCR in sera (one target only); in this group, positive AfQPCR was associated with positive GM in 14 patients, and in 10 patients AfQPCR was positive while GM remained negative.
Discussion
Our results confirm the usefulness of using a combination of biomarkers to improve early diagnosis of IA. In 9 cases, positive AfQPCR was able to confirm positive GM and imagery, thus allowing prompt, effective antifungal therapy to be initiated.
The usual biological diagnostic strategy requires another blood sample to confirm the previous positive GM [10] . The biological diagnosis strategy that we used reduces by one day the time required to assess two IA biomarkers of a different nature, nucleic acid and a polysaccharide antigen on the same blood sample.
In this study, AfQPCR was the first positive biomarker for probable IA in two patients; in one case, AfQPCR was positive one day before A. fumigatus culture of BALF (P15) and in the other case, AfQPCR was positive several days before GM (11 days, P14). Concerning the possible IA, AfQPCR was positive and the GM remained negative although the index did increase over time and thoracic imagery showed two nodules. This last case illustrates the fact that the current EORTC/MSG criteria classification, which does not yet include positive AfQPCR as biological criteria, may lead to an underestimation of IA infections. The question of the classification's limitations is also raised when considering the 14 non-IA patients with positive GM and AfQPCR. Some of them did not fit the risk factor criteria (n = 2), others had nonspecific thoracic imagery (n = 2) and most of them had no thoracic imagery performed concomitantly (n = 10).
Sixteen IA patients had no positive AfQPCR in sera. This may be explained by several factors: (i) the analytical sensitivity of our AfQPCR, which is 50% when combining both mitochondrial and ribosomal Af target, (ii) the very low fungal load in the blood of patients with IA, which is estimated to be around 30 to 100 fg/μl or less, and may lead to a false negative result because of the random dispersion of the few DNA copies [4, 11] , (iii) the reduction or even absence of free circulating fungal DNA due to prophylactic and curative antifungal treatments [3] .
Conclusion
On 16 patients, AfQPCR performed systematically in sera was positive at the time of positive GM in nine cases, confirming the benefit of screening with both AfPCR and GM to help with therapeutic decision-making. AfQPCR was positive only twice before GM, but considering the cost and the seriousness of IA, it is an important element. Screening high-risk patients using both AfQPCR and GM on the same serum sample is very feasible in a routine clinical setting.
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